These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 30651077)

  • 1. Alterations in the glycome after HDAC inhibition impact oncogenic potential in epigenetically plastic SW13 cells.
    Montgomery MR; Hull EE
    BMC Cancer; 2019 Jan; 19(1):79. PubMed ID: 30651077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition.
    Davis MR; Daggett JJ; Pascual AS; Lam JM; Leyva KJ; Cooper KE; Hull EE
    BMC Cancer; 2016 May; 16():316. PubMed ID: 27188282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
    Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
    Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of the tumor suppressor C-terminal Src kinase (Csk)-binding protein (Cbp)/PAG1 is mediated by epigenetic histone modifications via the mitogen-activated protein kinase (MAPK)/phosphatidylinositol 3-kinase (PI3K) pathway.
    Suzuki K; Oneyama C; Kimura H; Tajima S; Okada M
    J Biol Chem; 2011 May; 286(18):15698-706. PubMed ID: 21388951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Karyotypically abnormal human ESCs are sensitive to HDAC inhibitors and show altered regulation of genes linked to cancers and neurological diseases.
    Lund RJ; Emani MR; Barbaric I; Kivinen V; Jones M; Baker D; Gokhale P; Nykter M; Lahesmaa R; Andrews PW
    Stem Cell Res; 2013 Nov; 11(3):1022-36. PubMed ID: 23941963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma.
    Buurman R; Sandbothe M; Schlegelberger B; Skawran B
    Eur J Med Res; 2016 Jun; 21(1):26. PubMed ID: 27342975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
    Beyer M; Kiweler N; Mahboobi S; Krämer OH
    Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic modulation of the HeLa cell membrane N-glycome.
    Horvat T; Mužinić A; Barišić D; Bosnar MH; Zoldoš V
    Biochim Biophys Acta; 2012 Sep; 1820(9):1412-9. PubMed ID: 22192783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
    Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
    Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC Inhibitor-Induced Mitotic Arrest Is Mediated by Eg5/KIF11 Acetylation.
    Nalawansha DA; Gomes ID; Wambua MK; Pflum MKH
    Cell Chem Biol; 2017 Apr; 24(4):481-492.e5. PubMed ID: 28392145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel strategy for mammalian cell surface glycome profiling using lectin microarray.
    Tateno H; Uchiyama N; Kuno A; Togayachi A; Sato T; Narimatsu H; Hirabayashi J
    Glycobiology; 2007 Oct; 17(10):1138-46. PubMed ID: 17693441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury.
    Marumo T; Hishikawa K; Yoshikawa M; Hirahashi J; Kawachi S; Fujita T
    Am J Physiol Renal Physiol; 2010 Jan; 298(1):F133-41. PubMed ID: 19906951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Histone Deacetylase Inhibition on the Expression of Multidrug Resistance-associated Protein 2 in a Human Placental Trophoblast Cell Line.
    Duan HY; Ma D; Zhou KY; Wang T; Zhang Y; Li YF; Wu JL; Hua YM; Wang C
    Chin Med J (Engl); 2017 Jun; 130(11):1352-1360. PubMed ID: 28524836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
    Xiao JJ; Huang Y; Dai Z; Sadée W; Chen J; Liu S; Marcucci G; Byrd J; Covey JM; Wright J; Grever M; Chan KK
    J Pharmacol Exp Ther; 2005 Jul; 314(1):467-75. PubMed ID: 15833893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic Regulation of the Biosynthesis & Enzymatic Modification of Heparan Sulfate Proteoglycans: Implications for Tumorigenesis and Cancer Biomarkers.
    Hull EE; Montgomery MR; Leyva KJ
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28672878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
    Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cancer glycome: carbohydrates as mediators of metastasis.
    Glavey SV; Huynh D; Reagan MR; Manier S; Moschetta M; Kawano Y; Roccaro AM; Ghobrial IM; Joshi L; O'Dwyer ME
    Blood Rev; 2015 Jul; 29(4):269-79. PubMed ID: 25636501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.
    Xiao JJ; Foraker AB; Swaan PW; Liu S; Huang Y; Dai Z; Chen J; Sadée W; Byrd J; Marcucci G; Chan KK
    J Pharmacol Exp Ther; 2005 Apr; 313(1):268-76. PubMed ID: 15634944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.